ClinicalTrials.gg
TerminatedNCT03263767CYRICUpdated Jul 15, 2022

Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC

A Phase 2 interventional study of Fludarabine and Clofarabine in Graft Versus Host Disease, sponsored by Nantes University Hospital. Terminated at 1 site in France. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-07-15.

Sponsored by Nantes University Hospital · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Security criteria (MTD)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
47
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 54 studies in Graft vs Host Disease with a site in France — 10 open to participants now, 14 under way, 4 of them phase 3. Graft vs Host Disease · France.

Enrollment
30th of 47
47 · median 65
Started
2018
with 5 others
Phase 2
16 of 54
4 open now
Registered
30th of 54
by date
Lead sponsor
4 of 54
Nantes University Hospital

Among the 54 studies in Graft vs Host Disease with a site in France, this one is the 30th largest by enrollment of the 47 interventional ones that give a count, is one of 6 that started in 2018, is one of 16 in phase 2, and was the 30th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 148 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

10 of the 54 studies in Graft vs Host Disease with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 102 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 41 (40%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Graft vs Host Disease with a site in France, or all of them as a file.
02

Study summary

Acute or chronic graft versus host disease is still the major complication of stem cells transplantation regarding morbidity and mortality.

Recently, high dose cyclophosphamide utilization early after post-transplantation (day+ 3 and +4) not only for patients with HLA- haploidentical donor but also for patients with Human Leukocyte Antigen (HLA)-compatible donor, showed a great control of graft versus host disease after transplantation, allowing to consider stopping immunosuppressive treatment after the transplantation (Neoral=cyclosporine, cell-cept=mycophenolate mofetil). Indeed, this step has already been completed in myeloablative transplantation in adult patients.

This approach could enable to avoid in the end several complications related to long term immunosuppressive drugs administration, while promoting quicker immunity recovery.

Read the detailed description

The BALTIMORE conditioning regiment will be used in this study with peripheral stem cell transplantation and fludarabine will be replaced by clofarabine for myeloid diseases (Acute Myeloide Leukemia, Myelodysplasia , myelofibrosis, Chronic Myeoloid Leukemia..) because of better antitumoral activity in this setting.

03

Conditions studied

  • Graft Versus Host Disease

Browse trials for

Keywords

  • Peripheral haemopoietic stem cell transplant
  • High dose cyclophosphamide
  • acute GVHD
  • allogenic transplantation
  • RIC (reduced-intensity conditioning)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adults ≤ 70 years old
  • indication to stem cells transplantation with reduced-intensity conditioning regimen
  • with a HLA-compatible familial 10/10 or non-familial donor
  • Written signed form
  • woman with under efficient control birth method during the trial and up to 12 months after cyclophosphamide stop
  • men under efficient control birth method during the trial and up to 6 months after cyclophosphamide stop
  • Negative serology to B and C hepatitis and to
  • Affiliated to social security

Exclusion criteria

Exclusion Criteria:

    • Eligible to myeloablative contioning regimen
  • Other progressive disease or history of prior other malignancy in the last two years, with the exception of: curatively treated basal cell carcinoma or carcinoma in situ of the cervix
  • Progressive mental illness disease
  • Pregnant or Breastfeeding woman
  • woman with without any efficient control birth
  • Serious concomitant infection and not controlled
  • to allogenic transplantation, especially:

    • Cardiac: \<45% assessed by transthoracic echography or isotopic method (isotopic gamma-angiography)
    • Respiratory: DLCO limiting fludarabine and busulfan use (DLCO\< 40% of theorical value)
    • Renal: \< 60ml/min ( method)
    • Hepatic: transaminases >5 Uper Per Normal (UPN) or > 2 UPN
  • Contra-indications to cyclophosphamide:

    • Urinary tract infections
    • Acute urothelial toxicity due to cytotoxic chemotherapy or to radiotherapy
    • Obstruction of urines flow
    • Pre-existing hemorrhagic cystitis
    • Yellow fever vaccination
  • Cardiac condition preventing high dose cyclophosphamide utilization :

    • (NYHA) functional class II, III or IV
    • Rhythmic, valvular or ischemic cardiomyopathy
  • Minor
  • Patient under guardianship or curatorship
  • Patient under judicial protection
  • Known or suspected to cyclophosphamide
  • Known or suspected hypersensitivity to rabbit proteins
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    LYMPHOID HEMOPATHY without ATG

    patients with lymphoid hemopathy

    Drug: Fludarabine · Radiation: Full body irradiation · Drug: Cyclophosphamide · Other: stem cell transplantation · Other: nuclear cells

  • Experimental
    MYELOID HEMOPATHY without ATG

    patients with myeloid hemopathy

    Drug: Clofarabine · Radiation: Full body irradiation · Drug: Cyclophosphamide · Other: stem cell transplantation · Other: nuclear cells

  • Experimental
    LYMPHOID HEMOPATHY witH ATG

    patients inclued after 14 dec 2020, received a conditionnement regimen with ATG on Day -2 to reduce GVHD GRADE 1-2 incidence

    Drug: Fludarabine · Radiation: Full body irradiation · Drug: Cyclophosphamide · Other: stem cell transplantation · Other: nuclear cells · Drug: Thymoglobulin Injectable Product

  • Experimental
    MYELOID HEMOPATHY with ATG

    patients inclued after 14 dec 2020, received a conditionnement regimen with ATG on Day -2 to reduce GVHD GRADE 1-2 incidence

    Drug: Clofarabine · Radiation: Full body irradiation · Drug: Cyclophosphamide · Other: stem cell transplantation · Other: nuclear cells · Drug: Thymoglobulin Injectable Product

Interventions

  • 30 mg/m² Intravenous 5 days from Day-6 to Day-2

  • 30 mg/m² Intravenous 5 days from Day-6 to Day-2

  • RadiationFull body irradiation

    2 grays at Day-1

  • 14 mg/kg intravenous 2 days at Day - 6 and day -5

  • 50 mg/kg intravenous 2 days at day +3 and day +4

    Also known as: hight dose

  • Otherstem cell transplantation

    at D0 intraveinous Depending on donor : the stem cells will be extracted from blood (CD34+) or from bone marrow (CD34+ and nuclear cells)

    Also known as: graft

  • Othernuclear cells

    CD3+ cells if needed after transplantation

    Also known as: Donor Lymphocytes Injection (DLI)

  • DrugThymoglobulinStudies of ThymoglobulinThymoglobulin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    At day -2 2.5 mg/kg for patients inclued after 14 dec 2020

    Also known as: ATG

06

What researchers measure

Primary outcomes

  1. Incidence of grade 3 and 4 acute GVHD cortico-resistant

    acute GVHD will be evaluated from International Mount Sinai criteria

    Time frame: 100 days after transplantation

Secondary outcomes

  1. Engraftment

    number of days in aplasia (neutrophils\< 0.5 Giga/L and platelets\<20 G/l, number of transfusions (red blood and platelets)

    Time frame: one year

  2. Engraftment

    chimerism

    Time frame: one year

  3. disease free survival (DFS)

    blood and bone marrow analysis

    Time frame: one year, the last follow-up visit

  4. Overall survival (OS)

    clinical follow-up

    Time frame: one year, the last follow-up visit

  5. graft and relapse free survival

    time between Day O and relapse

    Time frame: one year

  6. chronic GVHD

    chronic GVHD will be assessed with NCI criteria for evaluation of chronic GVHD

    Time frame: one year

  7. non relapse mortality (NRM)

    number of death unrelated to relapse or disease progression

    Time frame: last follow-up visit

  8. Chimerism

    proportion of full and mixed donor chimerism

    Time frame: 1, 2, 3, 6 and 12 months after transplantation

  9. Immune reconstitution

    lymphocytes, monocytes, T4, T8, Natural Killer (NK), B cells rates

    Time frame: 3, 6 and 12 months after transplantation

  10. Identification of ghost factors associated with GVHD

    Statistical Models to Identify Subjects with Ghost Prognosis Factors Nguyen JM. 2015

    Time frame: one year

  11. Adverse events of grade 3 and 4 after transplantation

    time of occurring and frequency of grade 3 and grade 4 adverse events (CTCAE criteria)

    Time frame: one year

  12. Infections frequency

    time of occurring and frequency of viral (CytoMegalo Virus, Epstein Barr virus , BKV, adenovirus), bacterial, parasite and yeast infections, evaluated by Polymerase Chain Reaction (PCR), blood and urines cultures, biopsy if applicable

    Time frame: one year

  13. compare OS between patients with ATG and patients without ATG

    OS

    Time frame: one year, last follow-up visit

  14. compare grade 2-4 and 3-4 acute GVHD between patients with ATG and patients without ATG

    acute GVHD will be evaluated from International Mount Sinai criteria

    Time frame: one year

  15. compare chronic GVHD between patients with ATG and patients without ATG

    chronic GVHD will be assessed with NCI criteria for evaluation of chronic GVHD

    Time frame: one year

  16. compare DFS between patients with ATG and patients without ATG

    DFS

    Time frame: one year, last follow-up visit

  17. compare Relapse between patients with ATG and patients without ATG

    Relapse

    Time frame: one year, last follow-up visit

  18. compare NRM between patients with ATG and patients without ATG

    NRM

    Time frame: one year, last follow-up visit

  19. compare Infections frequency between patients with ATG and patients without ATG

    time of occurring and frequency of viral (CytoMegalo Virus, Epstein Barr virus , BKV, adenovirus), bacterial, parasite and yeast infections, evaluated by Polymerase Chain Reaction (PCR), blood and urines cultures, biopsy if applicable

    Time frame: one year

07

Study locations

1 site
  • Nantes Uh
    Nantes, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Oct 2021, 45 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2017
First posted
Aug 28, 2017
StartActual
Jan 15, 2018
Primary completionActual
Oct 21, 2021
CompletionActual
Jun 21, 2022
Last update
Jul 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03263767
Responsible party
Sponsor
First posted
Aug 28, 2017
Start date
Jan 15, 2018
Primary completion
Oct 21, 2021
Completion
Jun 21, 2022
Last update
Jul 15, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion